Education
About Us
Working with TipRanks
Follow Us
Medpace Holdings (MEDP)
NASDAQ:MEDP
Earnings Data
Report Date
Apr 21, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
3.06Last Year’s EPS
3.2Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 10, 2025
|% Change Since: -16.02%
|Next Earnings Date:Apr 21, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. While the company achieved significant revenue and income growth in 2024, challenges such as a weak book-to-bill ratio, decrease in new business awards, and elevated cancellations pose concerns for 2025. The guidance for 2025 indicates a cautious outlook with flat to modest revenue growth expected.Company Guidance
During Medpace Holdings, Inc.'s fourth quarter and full year 2024 earnings call, the company provided guidance for 2025, projecting total revenue between $2.11 billion and $2.21 billion, representing flat to 4.8% growth over 2024's $2.11 billion revenue. The EBITDA is expected to range from $462 million to $492 million, indicating a decline of 3.8% to growth of 2.5% compared to 2024's $480.2 million. Net income is forecasted between $378 million and $402 million, with an effective tax rate of 18% to 19%. The earnings per diluted share are anticipated to be between $11.93 and $12.69. The company aims to achieve a book-to-bill ratio above 1.15 in the second half of the year, despite a challenging backdrop due to high cancellations in 2024 and a slightly weakened business environment.Revenue Growth
Fourth quarter revenue was $536.6 million, a year-over-year increase of 7.7%. Full year 2024 revenue was $2.11 billion, an 11.8% increase from 2023.
EBITDA and Net Income Growth
Fourth quarter EBITDA was $133.5 million, a 39.3% increase compared to Q4 2023. Full year EBITDA was $480.2 million, a 32.5% increase from 2023. Net income for Q4 was $117 million, a 49.5% increase compared to Q4 2023.
Improved EBITDA Margin
EBITDA margin in Q4 was 24.9%, up from 19.2% in the prior year period. Full year EBITDA margin was 22.8% compared to 19.2% in 2023.
Strong Cash Flow
Generated $190.7 million in cash flow from operating activities in Q4, with $669.4 million in cash as of December 31, 2024.
---
MEDP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MEDP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 10, 2025 | $354.51 | $327.86 | -7.52% |
| Oct 21, 2024 | $352.92 | $326.54 | -7.47% |
| Jul 22, 2024 | $437.18 | $357.30 | -18.27% |
| Apr 22, 2024 | $376.26 | $407.15 | +8.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Medpace Holdings (MEDP) report earnings?
Medpace Holdings (MEDP) is schdueled to report earning on Apr 21, 2025, TBA Not Confirmed.
What is Medpace Holdings (MEDP) earnings time?
Medpace Holdings (MEDP) earnings time is at Apr 21, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MEDP EPS forecast?
MEDP EPS forecast for the fiscal quarter 2025 (Q1) is 3.06.
---